Mounika V, P Indumathi K, Siluvai Sibyl, G Krishnaprakash
Department of Public Health Dentistry, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur, IND.
Cureus. 2024 Nov 19;16(11):e74052. doi: 10.7759/cureus.74052. eCollection 2024 Nov.
Carbon monoxide (CO) has medicinal potential and harmful qualities. However, excessive exposure to CO can lead to severe organ failure. CO is exogenously and endogenously generated within the human body. Ongoing research aims to uncover the beneficial aspects of CO. It serves as a biomarker for inflammation and other serious illnesses. Preclinical trials exploring CO's application have indicated potential benefits in addressing conditions such as Ischemia, Tendonitis, Neuropathic pain, and even cancer therapy. Cardiovascular disease emerges as a particularly promising target for CO therapy due to its potent vasodilatory effects. While research into CO-based therapeutics has shown promise in experimental and preclinical settings, clinical translation and widespread adoption remain in the early stages. This review will illuminate the advantageous role of CO as a biomarker alongside the obstacles and challenges associated with its implementation.
一氧化碳（CO）具有药用潜力和有害特性。然而，过度暴露于CO会导致严重的器官衰竭。CO在人体内由外源性和内源性产生。正在进行的研究旨在揭示CO的有益方面。它可作为炎症和其他严重疾病的生物标志物。探索CO应用的临床前试验表明，在治疗诸如缺血、肌腱炎、神经性疼痛甚至癌症治疗等病症方面具有潜在益处。由于其强大的血管舒张作用，心血管疾病成为CO治疗特别有前景的靶点。虽然基于CO的治疗方法在实验和临床前环境中已显示出前景，但临床转化和广泛应用仍处于早期阶段。本综述将阐明CO作为生物标志物的有利作用以及与其实施相关的障碍和挑战。
